FDA Not Pursuing Ban on Drug DTC Ads, Makary says

FDA commissioner Marty Makary indicated this week that the agency is not planning to eliminate direct-to-consumer (DTC) pharmaceutical advertising, even as it ramps up enforcement against misleading promotions. Speaking at the DTC National conference on 4/21, Makary said the agency does not intend to pursue policies that would effectively end the standard 60- to 90-second television drug advertisement format, according to a summary of the discussion published by DTC Perspectives.

The remarks come amid ongoing debate within the administration over the future of DTC advertising. HHS secretary Robert F. Kennedy Jr. previously said he would support banning such ads altogether, raising concerns across the pharmaceutical and advertising industries.

Makary, however, suggested a more incremental approach focused on enforcement rather than sweeping restrictions. When asked whether he is under pressure from HHS to further limit DTC advertising, Makary said he is not, citing constitutional considerations around commercial free speech.

Instead, FDA is intensifying oversight of promotional claims. Since 9/2025, the agency’s Office of Prescription Drug Promotion has issued 72 untitled letters to drugmakers over potentially misleading advertisements, a sharp increase from just one such letter issued across 2023 and 2024.

Makary said this enforcement strategy is intended to ensure “fair balance” in drug advertising — meaning that benefits and risks are presented accurately — while preserving the broader framework that allows companies to market directly to consumers.

At the same time, the commissioner signaled openness to revisiting existing regulatory standards, including the “adequate provision” requirement that governs how risk information is presented in broadcast ads. He described the current framework as insufficient and invited industry input on potential reforms.

The FDA is also encouraging pharmaceutical companies to engage earlier with regulators when developing DTC campaigns, including through pre-clearance discussions or informal consultations, in an effort to avoid compliance issues after ads are released.

Makary emphasized that future enforcement will likely focus on ads that overstate a drug’s benefits. Recent Warning Letters have targeted campaigns portraying patients as dramatically transformed by treatment when clinical data do not support such outcomes.

Despite heightened scrutiny, industry participants at the conference appeared reassured that DTC advertising — particularly on television — will remain viable, albeit under stricter standards. Observers expect pharmaceutical companies to adopt more conservative messaging and tone down highly stylized imagery often used in ads, according to DTC Perspectives.

Makary’s appearance at the conference marked the first time a sitting FDA commissioner has attended the event, underscoring the agency’s effort to engage more directly with industry stakeholders as it recalibrates its approach to drug advertising.